Abstract: In some embodiments, the present invention provides an exemplary computer system that includes at least the following components: at least one processor; a non-transitory memory storing software instructions; and where, when executing the software instructions by the processor, the computer system is configured to perform at least: controlling a plurality of first software objects; controlling a plurality of second software objects; controlling a plurality of third software object; where each software object includes at least one property programmed with at least one trigger condition and at least one programmed action; where the at least one pre-programmed action is configured to dynamically change a value of at least one property of at least one other software object based on: i) the at least one trigger condition; and ii) a value of at least one other property.

Abstract: A system that is configured for varying light spectrum provided to plants based on sensor input to optimize plant health and growth. Preferred embodiments of the inventive concepts include an infrastructure grid of mesh networked smart drivers as part of the lighting system. The smart drivers communicate with sensors, with other smart drivers on the mesh network, and with control system software that can be implemented as a mobile application or as a cloud based solution.

Abstract: A Smart ANSI Microcontroller is provided to retrofit preexisting light fixtures. The preexisting light fixtures are configured with 5 pin or 7 pin ANSI receptacles. The Smart ANSI Microcontroller is configured to accept a variety of control signals and to control the power output of the driver of the preexisting driver of the luminaire in order to control the light output of the luminaire. The Smart ANSI Microcontroller is configured with a 5 pin or 7 pin ANSI male connector that is configured for mating engagement with the 5 pin or 7 pin female ANSI connector found in typical prior art luminaires, such as street lamps. The Smart ANSI Microcontroller allows for contemporary accessory light controllers to be utilized with the preexisting luminaires. The contemporary light controllers can be configured to connect to the Smart ANSI Microcontroller via wireless and/or wired connection.

Abstract: A Programmable Smart Module configured to recognize control and dimming standards provided by connected sensor(s) and wireless input control and to recognize the control and dimming standards of a driver connected to the Programmable Smart Module. The Programmable Smart Module is thus configured to accept the control and/or dimming standard and to provide control to the Driver in the standard the Driver accepts. The Programmable Smart Module allows for a single construct of a smart module to be utilized with a variety of control standards and/or Drivers. The Programmable Smart Module further include wireless functionality to provide for wireless programmability, wireless control of the Programmable Smart Module, and/or wireless control of other connected Programmable Smart Modules for the control of additional luminaires in a mesh network.

Abstract: A Smart ANSI Microcontroller is provided to retrofit preexisting light fixtures. The preexisting light fixtures are configured with 5 pin or 7 pin ANSI receptacles. The Smart ANSI Microcontroller is configured to accept a variety of control signals and to control the power output of the driver of the preexisting driver of the luminaire in order to control the light output of the luminaire. The Smart ANSI Microcontroller is configured with a 5 pin or 7 pin ANSI male connector that is configured for mating engagement with the 5 pin or 7 pin female ANSI connector found in typical prior art luminaires, such as street lamps. The Smart ANSI Microcontroller allows for contemporary accessory light controllers to be utilized with the preexisting luminaires. The contemporary light controllers can be configured to connect to the Smart ANSI Microcontroller via wireless and/or wired connection.

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: Benzodiazepine dimers having a structure represented by wherein X comprises a heteroaromatic moiety and is as further defined in the application; R1 is and the other variables in formulae (I), (Ia), and (Ib) are as defined in the application. Such dimers are useful as anti-cancer agents, especially when used in an antibody-drug conjugate (ADC).

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The Formula (I) imidazotriazines inhibit protein kinase activity thereby making them useful as anticancer agents.

Abstract: The invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity thereby making them useful as anticancer agents and for the treatment of Alzheimer's Disease.